Related Experiment Video
Updated: Apr 14, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display
Pradeep M Nair1, Heather Flores2, Alvin Gogineni3
1Cancer Immunology.
Abstract:
TNF superfamily death ligands are expressed on the surface of immune cells and can trigger apoptosis in susceptible cancer cells by engaging cognate death receptors. A recombinant soluble protein comprising the ectodomain of Apo2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) has shown remarkable preclinical anticancer activity but lacked broad efficacy in patients, possibly owing to insufficient exposure or potency. We observed that antibody cross-linking substantially enhanced cytotoxicity of soluble Apo2L/TRAIL against diverse cancer cell lines. Presentation of the ligand on glass-supported lipid bilayers enhanced its ability to drive receptor microclustering and apoptotic signaling. Furthermore, covalent surface attachment of Apo2L/TRAIL onto liposomes--synthetic lipid-bilayer nanospheres--similarly augmented activity. In vivo, liposome-displayed Apo2L/TRAIL achieved markedly better exposure and antitumor activity. Thus, covalent synthetic-membrane attachment of a cell-surface ligand enhances efficacy, increasing therapeutic potential. These findings have translational implications for liposomal approaches as well as for Apo2L/TRAIL and other clinically relevant TNF ligands.
Insights
Attaching Apo2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) to synthetic membranes, like liposomes, significantly boosts its cancer-killing ability. This approach enhances drug exposure and therapeutic potential for cancer treatment.
Area of Science:
- Immunology
- Biochemistry
- Nanotechnology
Background:
- Tumor necrosis factor (TNF) superfamily ligands induce apoptosis in cancer cells via death receptors.
- Soluble Apo2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) shows preclinical anticancer promise but has limited clinical efficacy.
- Enhanced ligand presentation may improve Apo2L/TRAIL potency and exposure.
Purpose of the Study:
- To investigate methods for enhancing the anticancer efficacy of Apo2L/TRAIL.
- To explore the impact of surface presentation and cross-linking on Apo2L/TRAIL activity.
- To evaluate the in vivo therapeutic potential of liposome-displayed Apo2L/TRAIL.
Main Methods:
- Antibody cross-linking of soluble Apo2L/TRAIL.
- Presentation of Apo2L/TRAIL on glass-supported lipid bilayers.
- Covalent attachment of Apo2L/TRAIL onto liposomes.
- Assessment of cytotoxicity against cancer cell lines.
- In vivo studies evaluating drug exposure and antitumor activity.
Main Results:
- Antibody cross-linking significantly enhanced Apo2L/TRAIL cytotoxicity.
- Lipid bilayer presentation improved receptor microclustering and apoptotic signaling.
- Liposome-displayed Apo2L/TRAIL demonstrated superior in vivo exposure and antitumor effects.
- Covalent surface attachment markedly augmented Apo2L/TRAIL efficacy.
Conclusions:
- Covalent synthetic-membrane attachment of Apo2L/TRAIL enhances its therapeutic efficacy.
- Liposomal delivery systems offer a promising strategy for improving Apo2L/TRAIL-based cancer therapy.
- These findings have translational implications for TNF ligand-based therapeutics.
